ICMR's clearance on using convalescent plasma therapy

ICMR's clearance on using convalescent plasma therapy

Context

The U.S. FDA and India’s ICMR have approved the use of plasma from recovered COVID-19 patients only for trial purposes.

With the ethics committee approval in hand on May 8, the ICMR cleared the last hurdle to conduct a multicentric phase-2 trial using convalescent plasma on COVID-19 patients with moderate illness.

Phase 2 trial- to check the efficacy of Plasma therapy

Its three feasibility studies in about 20 severely ill patients found the therapy to be safe and able to resolve illness or improve the clinical symptoms.
Since safety of convalescent plasma from people who have recovered from COVID-19 illness is not a huge concern, the first stage of the human clinical trial has been skipped; the ICMR will instead study plasma safety and efficacy in a phase-2 trial with 452 patients.
The patients with moderate COVID-19 illness will be randomly assigned to receive either convalescent plasma (226 participants) or only standard of care (control group).
The primary outcomes of the trial in 21 hospitals that will be studied include prevention of illness from progressing to a severe form, and avoidance of deaths from all causes at 28 days after plasma infusion.
And key secondary outcomes will include resolution of symptoms, reduction in hospital stay and respiratory support.
Plasma will be collected from donors 28 days after they make a complete recovery from illness or are symptom-free and have more than the required level of antibodies against the novel coronavirus.
Molecular and also other routine tests will be done before plasma use.

Convalescent plasma therapy

Convalescent plasma therapy, about a century old, has shown some benefit in treating measles, chickenpox and rabies.

Small studies have shown faster clearance of virus in the case of MERS and SARS if given early in the course of the disease .

Issues in Convalescent plasma therapy

No randomised controlled studies have been carried out.
No benefit was seen in 2015 on some Ebola patients treated with convalescent plasma in Guinea.
Only three small studies involving 21 COVID-19 patients have been carried out but not in trials where the participants were randomised with a control arm.
Till date, there is a dearth of randomised controlled trials that clearly demonstrate the efficacy of convalescent plasma therapy for any infectious disease, including COVID-19.

Way Ahead

Even in the absence of any effective treatment or a vaccine, the pandemic provides an opportunity to ascertain the clinical benefits of plasma therapy through randomised controlled trials.

The ICMR’s insistence on an evidence-based approach to plasma therapy is in contrast to the cavalier manner in which it approved the anti-malarial hydroxychloroquine, as a prophylaxis(treatment given or action taken to prevent disease) for coronavirus without carrying out any trial and relying on evidence that was slim and intended only for treatment, and also when the risks were unknown.

If the trial outcomes are overwhelmingly positive, the agency would be ethically obliged to recommend plasma therapy as a standard of care for COVID-19 patients.

Source: TH

Join Our Telegram

Polar vortex brings spring snow

Feluda Test

E-pharmacies

08 Mar, 23
SHARE

E-pharmacies The Ministry of Health sent "show cause" letters to at least 20 businesses in February 2023 for online drug sales, including Tata-1mg, Flipkart, Apollo, PharmEasy, Amazon, and Reliance Netmeds. What is e-pharmacy? E-pharmacy refers to the purchasing and selling of drugs and other pharmaceutical products through a

Punchhi Commission Report

08 Mar, 23
SHARE

Punchhi Commission Report The Punchhi Commission's report on relations between the federal government and its constituent states will now be reviewed for state responses, according to the Union Ministry of Home Affairs (MHA). Historical Background: A Commission on Centre-State Relations was established by the Indian government,

Indo-German Relations

08 Mar, 23
SHARE

Indo-German Relations Olaf Scholz, the Chancellor of Germany, recently paid a bilateral visit to India. It is Scholz's first trip to India after taking office as German Chancellor in December 2021, ending Angela Merkel's illustrious 16-year reign. About the news: The visit of the German chancellor is significant because i

India Denmark Cooperation

07 Mar, 23
SHARE

India Denmark Cooperation During the "India-Denmark: Partners for Green and Sustainable Development Conference" in New Delhi, the Union Minister for Environment, Forests, and Climate Change said that India and Denmark can work together to show that reaching ambitious climate and sustainable energy targets is possible. Since the Gr

Mob lynching and Cow Vigilantism

07 Mar, 23
SHARE

Mob lynching and Cow Vigilantism The recent lynching and burning of two men in Haryana on the basis of allegations of unlawful cow slaughter, smuggling, or transportation bring attention to the problem of mob lynching. About cow vigilantism: Mob attacks carried out in the guise of "cow protection" primarily target Mus